COIOSDeep risk insights through multi-disciplinary research across the globe
a dirt road in a foggy forest
Item refines Peer-reviewed Added

GLP-1 agonists show no effect on atrial fibrillation in obese HFpEF patients

In 470 matched pairs of obese, non-diabetic patients with heart failure with preserved ejection fraction, GLP-1 receptor agonist treatment was not associated with lower atrial fibrillation incidence (HR 0.86, 95% CI 0.53-1.39), while all-cause mortality was lower (HR 0.42, 95% CI 0.23-0.75).

A retrospective analysis of TriNetX electronic health records compared obese, non-diabetic patients with heart failure with preserved ejection fraction who received GLP-1 receptor agonists against untreated patients, propensity-matched to 470 per arm. Incident atrial fibrillation did not differ between the groups (hazard ratio 0.86, 95% CI 0.53 to 1.39). All-cause mortality was lower in the treated group (hazard ratio 0.42, 95% CI 0.23 to 0.75), an estimate resting on a small number of events.

Why it is interesting: Separates the arrhythmia and survival signals for GLP-1 agonists in a phenotype where obesity is thought to drive both.

Source
Journal of Arrhythmia, 22 September 2026
Paper
Glucagon-Like Peptide-1 Agonists and the Incidence of Atrial Fibrillation in Obese Patients With Heart Failure With Preserved Ejection Fraction and No Diabetes
Authors
Rassam F, Lopez EK, Sass S, Srikulmontri T, Isaacs E, Malin J et al.
DOI
10.1002/joa3.70455
Type
Peer-reviewed article
Design
Propensity-matched retrospective cohort in the TriNetX federated network, 470 treated vs 470 untreated obese non-diabetic HFpEF patients
Verdict
Refines prior evidence
Driver
Heart and stroke
Driver
Obesity, diabetes and GLP-1
Free full text
Free to read at the publisher

Other drivers in Health today